As 2013 approaches its inevitable end, the investment world has begun to debate the presence of a "biotechnology bubble". That is to say, a discussion has begun with the objective of concluding whether or not the biotechnology industry has become an over-priced market fueled by its own momentum. If it has, the potential end result is an industry wide crash which will adversely affect companies and shareholders alike. However, this is unlikely. Sure, similar yearlong run-ups in other industries have been met with inevitable demise (most notably the housing crash and the dotcom boom) but biotechnology is different. Biotechnology is an industry in a class all its own. It is fueled by innovation and genius. Genius innovations, in the medical...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|